Published in AIDS on March 31, 2000
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother (2005) 2.76
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS (2008) 2.13
Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action (2010) 2.04
Adverse effects of antiretroviral therapy for HIV infection. CMAJ (2004) 2.04
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis (2004) 1.94
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis (2010) 1.70
Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy. AIDS (2010) 1.68
Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol (2001) 1.65
Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr (2009) 1.54
A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh. Indian J Pharmacol (2009) 1.47
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis (2010) 1.45
Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther (2007) 1.39
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One (2010) 1.37
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol (2005) 1.28
The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care (2012) 1.28
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis (2012) 1.26
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med (2004) 1.16
Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses (2008) 1.15
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol (2012) 1.11
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (2004) 1.09
A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategies. PLoS One (2012) 1.09
Evaluating competing adverse and beneficial outcomes using a mixture model. Stat Med (2008) 1.02
Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. J Gene Med (2010) 1.02
Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. J Int AIDS Soc (2010) 1.00
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis (2013) 0.99
Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users. HIV Med (2012) 0.98
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res (2011) 0.97
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr (2011) 0.97
Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDS (2006) 0.96
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. J Acquir Immune Defic Syndr (2016) 0.95
Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective. BMC Public Health (2012) 0.95
Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS One (2013) 0.94
Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil. AIDS Res Ther (2014) 0.94
Temporal trends in the discontinuation of first-line antiretroviral therapy. J Antimicrob Chemother (2014) 0.91
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS (2008) 0.91
Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Ther Clin Risk Manag (2012) 0.89
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br J Clin Pharmacol (2008) 0.89
Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India. PLoS One (2014) 0.87
The Reason for Regimen Change Among HIV/AIDS Patients Initiated on First Line Highly Active Antiretroviral Therapy in Southern Ethiopia. N Am J Med Sci (2012) 0.87
Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies. Epidemiology (2009) 0.86
Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathy. Biol Res Nurs (2009) 0.83
An analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitors. PLoS Comput Biol (2009) 0.83
Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. HIV Med (2014) 0.83
Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. MedGenMed (2006) 0.83
Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants. BMC Complement Altern Med (2009) 0.83
Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching. Infect Chemother (2015) 0.83
Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)? Eur J Epidemiol (2004) 0.82
Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors. Med Sci Monit (2013) 0.82
Antiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for 'test and treat' prevention strategy. AIDS Patient Care STDS (2013) 0.82
Symptom exacerbation and adherence to antiretroviral therapy during the menstrual cycle: a pilot study. Infect Dis Obstet Gynecol (2006) 0.82
Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. Clinicoecon Outcomes Res (2013) 0.81
Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. J Natl Med Assoc (2008) 0.81
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag (2013) 0.81
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. Antimicrob Agents Chemother (2008) 0.81
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. J Int AIDS Soc (2014) 0.81
Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression. PLoS One (2013) 0.80
Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One (2010) 0.79
Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr (2010) 0.78
Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph? PLoS One (2014) 0.78
Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in Ghana. Pan Afr Med J (2014) 0.78
Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. J Clin Pharmacol (2011) 0.77
Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study. BMC Infect Dis (2016) 0.77
A computational model of mitochondrial AZT metabolism. Biochem J (2005) 0.77
Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy (2011) 0.77
Unanticipated Effects of New Drug Availability on Antiretroviral Durability: Implications for Comparative Effectiveness Research. Open Forum Infect Dis (2016) 0.77
Highly active antiretroviral therapy. BMJ (2005) 0.75
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS One (2016) 0.75
Virus against virus (VIVI): a potential solution against HIV/AIDS. Int Arch Med (2014) 0.75
Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive Individuals. PLoS One (2016) 0.75
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort. Medicine (Baltimore) (2016) 0.75
The role of toxicity-related regimen changes in the development of antiretroviral resistance. AIDS Res Hum Retroviruses (2011) 0.75
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand. Pharmgenomics Pers Med (2015) 0.75
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infect Dis (2016) 0.75
Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infect Dis (2017) 0.75
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS One (2016) 0.75
Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, Nigeria. Ghana Med J (2014) 0.75
Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia. J Virus Erad (2016) 0.75
Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values? Eur J Epidemiol (2000) 0.75
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia. BMC Infect Dis (2017) 0.75
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med (1997) 7.11
Meta-analysis: principles and procedures. BMJ (1997) 6.87
Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health (1985) 5.53
Confounding in epidemiological studies: why "independent" effects may not be all they seem. BMJ (1992) 4.79
Social class differences in ischaemic heart disease in British men. Lancet (1987) 4.09
Prophylaxis after occupational exposure to HIV. BMJ (1997) 4.07
Smoking as "independent" risk factor for suicide: illustration of an artifact from observational epidemiology? Lancet (1992) 3.92
Measles outbreak on a cruise ship in the western Mediterranean, February 2014, preliminary report. Euro Surveill (2014) 3.87
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr (2001) 3.83
Identifying men at high risk of heart attacks: strategy for use in general practice. Br Med J (Clin Res Ed) (1986) 3.76
Cancer in the elderly: why so badly treated? Lancet (1990) 3.67
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Passive smoking and health: should we believe Philip Morris's "experts"? BMJ (1996) 2.76
A scoring system to identify men at high risk of a heart attack. Health Trends (1987) 2.58
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis (2001) 2.50
Association between hepatitis E virus and HIV infection in homosexual men. Lancet (1994) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ (1989) 2.47
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Risk factors for stroke in middle aged British men. BMJ (1991) 2.44
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group. Arch Intern Med (1998) 2.38
Man-to-woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men. J Acquir Immune Defic Syndr (1993) 2.36
Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst (1998) 2.32
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A (1994) 2.29
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27
Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med (2008) 2.26
Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 2.24
Inflation in epidemiology: "the proof and measurement of association between two things" revisited. BMJ (1996) 2.24
Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS (1996) 2.22
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood (1999) 2.10
Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA (1995) 2.08
Chikungunya in north-eastern Italy: a summing up of the outbreak. Euro Surveill (2007) 2.07
Cytotoxic necrotizing factor production by hemolytic strains of Escherichia coli causing extraintestinal infections. J Clin Microbiol (1987) 2.07
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res (1997) 2.05
AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology (2000) 2.05
A multicenter study of treatment of primary CNS lymphoma. Neurology (2002) 2.04
Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst (1999) 2.01
Cardio- and cerebrovascular events in HIV-infected persons. AIDS (2004) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet (1999) 1.95
Migration and geographic variations in ischaemic heart disease in Great Britain. Lancet (1989) 1.95
Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998. Lazio AIDS Surveillance Collaborative Group. AIDS (1999) 1.92
High frequency of invasive cervical cancer among female injecting drug users with AIDS in Italy. AIDS (1996) 1.92
The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis (1997) 1.90
Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS (1999) 1.89
Human immunodeficiency virus seroprevalence and condom use among female sex workers in Italy. Sex Transm Dis (1998) 1.87
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS (2001) 1.86
Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med (1996) 1.82
Immunodiffusion and agglutination tests for Candida in patients with neoplastic disease: inconsistent correlation of results with invasive infections. J Infect Dis (1977) 1.82
Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS (2000) 1.82
Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol (1999) 1.81
An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill (2007) 1.81
Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia. Lancet (1992) 1.81
Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis (2001) 1.77
Determinants of survival in progressive multifocal leukoencephalopathy. Neurology (2009) 1.77
ABO blood group and ischaemic heart disease in British men. BMJ (1990) 1.76
Rapid spread of HTLV-III infection among drug addicts in Italy. Lancet (1985) 1.75
High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men. Br Med J (Clin Res Ed) (1986) 1.73
Cancer incidence in a cohort of human immunodeficiency virus seroconverters. HIV Italian Seroconversion Study Group. Cancer (1997) 1.73
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood (2000) 1.69
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer (2003) 1.67
Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS (2000) 1.67
Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr (2000) 1.67
Brief report: disseminated mycobacteriosis caused by drug-resistant Mycobacterium triplex in a human immunodeficiency virus-infected patient during highly active antiretroviral therapy. Clin Infect Dis (2000) 1.65
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology (2011) 1.65
Disseminated human herpesvirus 6 infection in AIDS. Lancet (1993) 1.64
Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS (1996) 1.64
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med (2011) 1.64
Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. AIDS (2001) 1.64